Compounded Medication – Prescription Only

This product is a compounded injectable formulation containing retatrutide and is dispensed only
pursuant to a valid prescription issued by a licensed healthcare provider. Retatrutide is a
synthetic peptide that has been studied for its activity at multiple endocrine receptors, including
glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypein (GIP), and
glucagon receptors. In compounding practice, retatrutide formulations may be prescribed when a
provider determines that individualized concentration, formulation, or dosing considerations are
clinically appropriate for a specific patient. This product is not available for self-selection and
may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA).
The FDA does not evaluate compounded formulations for safety, effectiveness, or quality.
Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific
prescription. This page provides general, non-therapeutic information for educational and
compliance purposes only. It does not describe intended use, therapeutic benefit, metabolic
effects, weight-related outcomes, glycemic control, appetite modulation, or expected clinical
results.

General Scientific Information (Non-Therapeutic)
Retatrutide has been described in scientific literature as a multi-receptor peptide studied under
controlled research conditions for its molecular structure and receptor-binding characteristics.
Research has examined interactions involving GLP-1, GIP, and glucagon receptor pathways in
laboratory and clinical study settings. These descriptions are provided solely for general
scientific context. No claims are made regarding safety, effectiveness, clinical outcomes,
metabolic changes, weight effects, or suitability for any particular condition.

Formulation Considerations
Some compounded formulations of retatrutide may include additional components such as
vitamin B-12 (cyanocobalamin), vitamin B-6 (pyridoxine), or ondansetron, as determined by the
prescribing healthcare provider. The inclusion of these components reflects formulation
preferences or individualized patient considerations and does not alter the regulatory status of the
compounded medication. The presence or absence of these components does not imply enhanced
effectiveness, mitigation of side effects, or altered clinical outcomes.

Contraindications
Retatrutide injection should not be used in individuals who have a known hypersensitivity or
allergy to retatrutide or any component of the compounded formulation; have a personal or
family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
(MEN 2); have experienced prior serious adverse reactions to peptide-based injectable therapies;
or have other conditions in which treatment with incretin- or glucagon-pathway agents is
contraindicated as determined by the prescribing healthcare provider. Use in pregnant or
breastfeeding individuals should occur only if a licensed healthcare provider determines that
potential risks and benefits have been carefully evaluated.

Warnings and Precautions
Peptide-based injectable agents acting on endocrine signaling pathways may be associated with
gastrointestinal effects and other systemic reactions. Caution is advised in individuals with a
history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or renal impairment.
Injectable administration should be performed only as prescribed and supervised by a licensed
healthcare provider. Patients should inform their healthcare provider of all medical conditions,
medications, and supplements prior to receiving this compounded formulation.

Potential Side Effects
Reported side effects associated with peptide-based injectable formulations studied in similar
pharmacologic classes may include nausea, vomiting, diarrhea, constipation, abdominal
discomfort, headache, dizziness, fatigue, or injection-site reactions such as redness, swelling, or
irritation. Serious adverse reactions are uncommon but may occur. Patients should seek
immediate medical attention if they experience severe abdominal pain, symptoms suggestive of
pancreatitis, signs of a severe allergic reaction, or other unexpected systemic symptoms.